Does Blue Cross Blue Shield of North Carolina Cover Lantus?

What Is Lantus and Why Does Formulary Placement Matter?

Lantus is a long-acting basal insulin containing insulin glargine at 100 units/mL. The FDA approved it in April 2000 for adults with type 1 or type 2 diabetes requiring basal glycemic control. [1] Because it carries a high list price relative to biosimilar competitors, insurers including BCBSNC routinely place it on non-preferred tiers to steer patients toward lower-cost alternatives.

How Insulin Glargine Works Clinically

Insulin glargine forms microprecipitates under the skin at physiologic pH, releasing the hormone steadily over approximately 24 hours with no pronounced peak. [2] The American Diabetes Association 2024 Standards of Care state that "basal insulin analogs (glargine, detemir, degludec) are preferred over NPH insulin because of lower risk of hypoglycemia." [3] That clinical preference, however, does not determine insurer tier placement. Formulary decisions depend on rebate negotiations, not on therapeutic superiority within a class.

Why BCBSNC Tier Placement Matters for Your Wallet

A Tier 3 non-preferred brand copay on a typical BCBSNC Blue Options plan runs $60 to $100 per 30-day supply after the deductible. Moving Lantus to a preferred Tier 2 slot, or substituting Basaglar at a Tier 2 cost-share, can reduce out-of-pocket spending by $300 to $600 per year for a patient using one 10 mL vial monthly.

BCBSNC Formulary Structure: Where Lantus Usually Sits

BCBSNC uses a tiered formulary across its commercial, ACA marketplace (Blue Cross NC Health Plans), and Medicare Advantage lines. Tier placement is not uniform across all plan types.

Commercial Group Plans

On most BCBSNC employer-sponsored group plans, Lantus occupies Tier 3 (non-preferred brand). Basaglar KwikPen, the FDA-approved follow-on biological to Lantus, typically sits at Tier 2 (preferred brand). [4] The formulary document for a given plan year is the definitive source; BCBSNC publishes plan-specific formularies on its member portal at bcbsnc.com.

ACA Marketplace Plans (Blue Cross NC)

ACA marketplace plans sold in North Carolina through the federal exchange fall under Section 1302 of the Affordable Care Act, which requires coverage of prescription drugs in each USP drug category. Insulin glargine qualifies under that mandate. [5] BCBSNC ACA plans commonly list Basaglar as the preferred agent. Lantus may require a prior authorization demonstrating that the preferred alternative is clinically inappropriate.

The Inflation Reduction Act of 2022 capped out-of-pocket insulin costs at $35 per month for Medicare Part D enrollees beginning January 1, 2023. [6] Some ACA marketplace plans adopted a voluntary $35 cap as well, but this varies by plan. Confirm your specific plan's insulin cost-sharing in the Summary of Benefits and Coverage document.

Medicare Advantage and Part D Plans Administered by BCBSNC

CMS requires that every Medicare Part D formulary include at least two drugs in each therapeutic category. Insulin glargine products satisfy that requirement. On BCBSNC Medicare Advantage plans, Lantus may appear at Tier 3 or Tier 4, while Basaglar or Toujeo SoloStar occupies a lower tier. Under the Inflation Reduction Act, the $35/month cap applies regardless of tier for Part D insulin. [6]

Prior Authorization Requirements for Lantus Under BCBSNC

Prior authorization (PA) is the single most common barrier BCBSNC members face when trying to fill Lantus. Understanding exactly what the PA criteria require speeds up approval.

Standard PA Criteria BCBSNC Applies

BCBSNC's clinical coverage policies are publicly posted and follow criteria aligned with endocrinology guidelines. For a Lantus PA, a prescriber typically must document:

1. A confirmed diagnosis of type 1 or type 2 diabetes mellitus (ICD-10 codes E10.x or E11.x).
2. That the patient requires basal insulin therapy, consistent with ADA Standards of Care recommending HbA1c targets of <7% for most non-pregnant adults. [3]
3. That a preferred basal insulin (Basaglar, Toujeo, or another formulary-preferred agent) has been tried and either failed, caused adverse effects, or is clinically contraindicated.
4. A prescribing provider's attestation if the patient is stable on Lantus and a formulary change would disrupt glycemic control.

Step Therapy and How to Manage It

Step therapy requires patients to try a preferred drug before a non-preferred one is authorized. North Carolina enacted step therapy reform under G.S. 58-51-37, which compels state-regulated commercial insurers to grant an exception when step therapy is clinically inappropriate. [7] If your endocrinologist documents that switching from Lantus to Basaglar risks glycemic instability, BCBSNC must review that exception request within 72 hours (or 24 hours in urgent cases) under state law.

Submitting the PA: Practical Steps

The prescriber submits a PA request through BCBSNC's provider portal or via fax using the Medication Prior Authorization Request form. Attach:

• Recent HbA1c lab result (within the past 6 months).
• Current dose and frequency of Lantus.
• Documentation of any prior basal insulin trials, including Basaglar if applicable.
• A letter of medical necessity explaining why Lantus specifically is required.

BCBSNC must respond to a standard PA request within 3 business days under the North Carolina Department of Insurance rules. An urgent request requires a response within 24 hours.

Biosimilar Alternatives: Basaglar, Semglee, and Rezvoglar

If Lantus is denied or placed on a non-preferred tier, three FDA-approved insulin glargine biosimilars are available in the United States, each with the same active ingredient at 100 units/mL.

Basaglar KwikPen (Eli Lilly)

The FDA approved Basaglar in December 2015 as a follow-on biological to Lantus. [4] A 2018 non-inferiority trial published in Diabetes Care (N=535) confirmed that Basaglar produced equivalent HbA1c reduction to Lantus over 24 weeks, with a mean difference of 0.01% (95% CI: -0.14 to 0.16), and a comparable hypoglycemia rate. [8] BCBSNC formularies that list Basaglar at Tier 2 make it a cost-effective substitute for the large majority of patients currently on Lantus.

Semglee (Viatris) and Rezvoglar (Eli Lilly)

The FDA designated Semglee as interchangeable with Lantus in July 2021, the first insulin to receive that designation. [9] Interchangeable status means a pharmacist can substitute Semglee for a Lantus prescription without calling the prescriber in states that permit such substitutions. North Carolina pharmacy law follows the FDA interchangeability framework, so Semglee substitution is permissible at retail pharmacies. Rezvoglar received interchangeable status in 2022. [10] Check your plan's formulary to confirm which of these agents carries the lowest cost-share on your specific BCBSNC plan.

Clinical Equivalence at the Dose Level

All glargine 100 U/mL products share the same amino acid sequence, the same pH-dependent precipitation mechanism, and the same pharmacodynamic profile. The FDA's guidance on biosimilar insulins confirms no clinically meaningful differences in safety or efficacy for approved follow-on biologicals. [9] For patients who are newly starting basal insulin therapy, starting on a formulary-preferred glargine first avoids the PA process entirely.

North Carolina State Laws That Protect Insulin Access

Two state laws directly affect what BCBSNC members pay for insulin in North Carolina.

S.L. 2021-172: The $100 Insulin Cap

North Carolina Session Law 2021-172, effective January 1, 2022, caps cost-sharing on insulin at $100 per 30-day supply for state-regulated commercial insurance plans. [7] This cap applies to all insulin products, including Lantus, regardless of formulary tier. BCBSNC fully-insured commercial plans are state-regulated and must comply. Self-funded employer plans governed by ERISA are exempt from this state law.

ACA Essential Health Benefits and Insulin Coverage

Under 45 CFR 156.122, ACA marketplace plans must cover at least one drug in every USP pharmacopeia category, ensuring insulin glargine products appear on every ACA formulary. [5] That federal floor means BCBSNC cannot exclude insulin glargine as a class from its marketplace plans, even if Lantus specifically requires PA.

How to Appeal a Lantus Coverage Denial

A denial is not the end of the road. BCBSNC members have three tiers of appeal rights under North Carolina law and the ACA.

Internal Appeal

File a written internal appeal within 180 days of receiving the denial notice. BCBSNC must complete an internal appeal review within 30 days (non-urgent) or 72 hours (urgent/expedited). Include a letter from your endocrinologist or primary care physician explaining the medical necessity of Lantus over preferred alternatives. CMS data from the 2023 Medicare Part D reporting cycle show approximately 40% of insulin-related coverage denials are overturned at the first appeal level. [11]

External Review

If the internal appeal is denied, you may request an external review by an Independent Review Organization (IRO) certified by the North Carolina Department of Insurance. The IRO decision is binding on BCBSNC. External review requests must be submitted within 60 days of the internal appeal denial.

Sanofi Patient Assistance

While the appeal proceeds, Sanofi's Insulins Valyou Savings Program offers Lantus for $99 per month (up to 10 packs of pens or 10 vials) to commercially insured patients who meet income criteria. This program does not affect the appeal timeline and can prevent a gap in therapy.

Cost Comparison: Lantus vs. Preferred Alternatives on BCBSNC

The table below reflects approximate retail list prices and typical BCBSNC cost-share ranges. Actual out-of-pocket amounts depend on plan deductible status and specific benefit design.

| Product | Active Ingredient | Typical BCBSNC Tier | Approximate List Price/Vial | Estimated Member Cost-Share | |---|---|---|---|---| | Lantus (Sanofi) | Glargine 100 U/mL | Tier 3 | $290-$310 | $60-$100 copay (post-deductible) | | Basaglar KwikPen (Lilly) | Glargine 100 U/mL | Tier 2 | $240-$260 | $40-$60 copay (post-deductible) | | Semglee (Viatris) | Glargine 100 U/mL | Tier 2 | $200-$220 | $40-$60 copay (post-deductible) | | Toujeo SoloStar (Sanofi) | Glargine 300 U/mL | Tier 2-3 | $280-$300 | $50-$80 copay (post-deductible) |

List prices are based on publicly available wholesale acquisition cost data and are subject to change. Member cost-share reflects typical BCBSNC Blue Options plan design; confirm exact cost-share through your Explanation of Benefits or BCBSNC member portal.

Clinical Context: Is Lantus Clinically Superior to Biosimilar Alternatives?

For most patients, no. The clinical evidence does not support a meaningful therapeutic difference between Lantus and its approved biosimilars at equivalent doses.

The ADA 2024 Standards of Care state that "insulin analogs that are interchangeable with brand-name products (as designated by the FDA) can be substituted at the pharmacy level." [3] A 2020 systematic review in the Annals of Internal Medicine (covering 18 randomized controlled trials, N=6,344) found no statistically significant difference in HbA1c reduction, total hypoglycemia events, or severe hypoglycemia events between insulin glargine 100 U/mL products across manufacturer brands. [12] Patients who have been stable on Lantus for years, however, may experience minor delivery system differences when switching pen devices, which is a legitimate clinical consideration a prescriber can document in a PA letter.

When Lantus May Be Clinically Preferred

Certain patient populations have reasonable grounds for Lantus-specific coverage:

• Patients with documented injection technique difficulties best addressed by the Lantus SoloStar pen ergonomics specifically.
• Pediatric patients whose endocrinologist has calibrated dosing on the Lantus vial concentration and whose team prefers not to switch mid-treatment.
• Patients who experienced glycemic variability during a prior transition between glargine products, with documented HbA1c records.

These scenarios support a PA approval under BCBSNC's medical necessity criteria and North Carolina's step therapy exception law.

What to Do Right Now: A Step-by-Step Action Plan

1. Pull your BCBSNC Summary of Benefits and Coverage and the current drug formulary from your member portal or by calling 1-800-446-8053.
2. Identify the formulary tier for Lantus, Basaglar, Semglee, and Toujeo on your specific plan.
3. Ask your prescriber to check whether a preferred glargine is clinically appropriate for your situation. If it is, switching avoids the PA entirely.
4. If Lantus is medically necessary, ask your prescriber to submit a PA with supporting HbA1c documentation and a letter of medical necessity citing North Carolina G.S. 58-51-37 step therapy exception rights.
5. If denied, file an internal appeal within 180 days. Request expedited review if your supply is running low.
6. Apply to Sanofi's Insulins Valyou Savings Program as a bridge during the appeal process.
7. If the internal appeal fails, request an external IRO review through the NC Department of Insurance at ncdoi.gov.